DOCSLIB.ORG

Virtual E-Abstract

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Virtual E-Abstract VIRTUAL E-ABSTRACT Theme: Stroke Strikes Fast, ResQ Faster! Virtual Conference Date: 14th August 2020 to 16th August 2020 Contents will be available online from 14th August to 14th September 2020 msconference2020.com Organised by: In Collaboration with: M S N A A L I A C Y I S S I Y A H N P A N S S O O I C T I TA A LI TIO BI N OF REHA MALAYSIA STROKE CONFERENCE 2020 ORGANISING COMMITTEE NEUROINTERVENTIONAL RADIOLOGIST SCIENTIFIC Chairperson: COMMITTEE Associate Professor Dr Hoo Fan Kee, • Professor Dr Ahmad Sobri Muda, Universiti Putra Universiti Putra Malaysia Malaysia Scientific Chairperson: • Professor Dr Rozman Zakaria, Universiti Kebangsaan Dr Irene Looi, Seberang Jaya Hospital Malaysia • Professor Dr Khairul Azmi Abdul Kadir, University of Co-Scientific Chairperson: Malaya Dr Wan Asyraf Wan Zaidi, Universiti Kebangsaan Malaysia • Dr Zulkifli Zaki Abdul Ghani, Hospital Sungai Buloh MSC VIRTUAL 2020 SCIENTIFIC COMMITTEE STROKE REHABILITATION SCIENTIFIC COMMITTEE • Professor Dr Hamidon Basri, Universiti Putra Malaysia • Dr Mazatulfazura SF Salim, Universiti Putra Malaysia • Dr Azliza binti Ibrahim, Universiti Putra Malaysia • Professor Lydia Abd Latiff, Regen Rehab Hospital • Associate Professor Dr Muzaimi Mustapha, Universiti • Dr Norhayati bt Hussein, Hospital Rehab Cheras Sains Malaysia Kubang Kerian • Dr Khairiah by Mohd Yatim, Hospital Tuanku Jaafar • Dr Abdul Hanif Khan Yusof Khan, Universiti Putra • Dr Maslina Bt Yazid, Hospital Tengku Ampuan Rahimah Malaysia • Dr Law Wan Chung, Sarawak General Hospital FAMILY MEDICINE SCIENTIFIC COMMITTEE • Associate Professor Dr. Ching Siew Mooi, Universiti Putra • Dr Neoh Kar Keong, Seberang Jaya Hospital Malaysia • Dr Loh Wei Chao, Universiti Putra Malaysia • Dr Navin Kumar Devaraj, Universiti Putra Malaysia • Dr Chia Peck Kee, Universiti Putra Malaysia • Dr Aneesa Abdul Rashid, Universiti Putra Malaysia • Dr Anna Misya’il Abdul Rashid, Universiti Putra Malaysia • Associate Professor Dr Aznida Firzah Abdul Aziz, • Dr Janudin Baharin, Universiti Putra Malaysia Universiti Kebangsaan Malaysia • Associate Professor Dr Liyana Najwa Inche Mat, RESEARCH SCIENTIFIC COMMITTEE Universiti Putra Malaysia • Datin Dr Sheamini Sivasampu, National Clinical Research • Associate Professor Dr Wan Aliaa Wan Sulaiman, Centre Universiti Putra Malaysia • Dr Amy Hwong Wen Yea, National Clinical Research Centre • Dr Norazida Ab Rahman, National Clinical Research GERIATRIC SCIENTIFIC COMMITTEE Centre • Professor Dr Tan Maw Pin, University of Malaya • Associate Professor Dr Muzaimi Mustapha, Universiti • Dr Tan Kit Mun, University of Malaya Sains Malaysia Kubang Kerian • Dr Cheah Wee Kooi, Hospital Taiping • Dr Kurubaran Ganasegeran, Clinical Research Centre • Dr Alan Ch’ng Swee Hock, Seberang Jaya Hospital Hospital Seberang Jaya • Dr Teh Hoon Lang, Hospital Sultanah Bahiyah Kedah • Dr Hor Chee Peng, Clinical Research Centre Hospital Seberang Jaya • Dr Ungku Ameen, Hospital Klang • Dr Loh Hong Chuan, Clinical Research Centre Hospital Universiti • Dr Mohamed Seenikatty Abdul Hakim, Seberang Jaya Teknologi MARA • Dr Abdul Hanif Khan Yusof Khan, Universiti Putra Emergency Department (ED) Scientific Committee Malaysia • Associate Professor Dr Iskasymar Ismail, Universiti Putra • Norshima Malaysia • Associate Professor Dr Mohd Idzwan, University of Malaya • Associate Professor Dr Kamarul Aryffin Baharudin, Universiti Sains Malaysia Kubang Kerian • Dr Chow Chee Toong, Seberang Jaya Hospital • Dr Sarah Shaikh Abdul Karim, Hospital Sungai Buloh • Dr Nik Azlan Nik Muhamad, Universiti Kebangsaan Malaysia • Dr Low Mook Yuang, Sarawak General Hospital 2 TABLE OF CONTENT E-Poster Presentation – Clinical 4 E-Poster Presentation – Non-Clinical 33 Oral Presentation – Clinical 42 Oral Presentation – Non-Clinical 59 2 3 E-Poster Presentation – Clinical 4 VIRTUAL E-ABSTRACT Stroke and Tocotrienols Unique Role in Neuroprotection CPP 01 (SATURN): Protocol Loh HC 1, Looi I1,2, Yanti Nasyuhana Sani3, Fung WY4, Lim SCS4, Yuen KH4, Nurzalina Abdul KK4 1Clinical Research Centre, Seberang Jaya Hospital, Ministry of Health Malaysia, Penang, Malaysia 2Medical Department, Seberang Jaya Hospital, Penang, Malaysia 3Department of Pharmacy, Hospital Sultanah Nur Zahirah, Terengganu, Malaysia 4School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia Introduction Stroke is a major health problem and the second leading cause of death worldwide. In Malaysia, it is the third largest cause of morbidity and mortality. To date, there is no clinically proven neuroprotective agent that can be used prophylactically to minimize the brain cells damage during a stroke nor is there any agent that can ameliorate or hasten the recovery after its attack. Tocotrienols have been reported to exert neuroprotective properties both in cell-based and animal studies. The neuroprotective properties were also demonstrated at the concentration or doses that are achievable in normal supplementation with tocotrienols in humans. Based on these encouraging results, we postulate that mixed tocotrienols from palm oil may indeed be beneficial in helping to improve neurological deficits in patients who have suffered a stroke attack. Method Treatment group given tocotrienols while the control group given placebo for 24 weeks with follow up every 12 weeks. Evaluation of study endpoints will be performed at week 24 (end of treatment phase). A safety follow-up visit will be performed up to 14 days after last study treatment administration. Results Efficacy parameter will be measured with assessment tools, ie. MRS, NIHSS, MBI, CLOX and TMT Parts A & B. The analyses will be performed using IBM SPSS Statistics. Descriptive statistics will be utilized for selected variables. All probability values will be used two-sided p-value < 0.05 will be considered as statistically significant. Conclusion We hypothesized that tocotrienols will reduce neurological deficit and improve functional outcomes after acute ischemic stroke. 4 5 MALAYSIA STROKE CONFERENCE 2020 Age On Prevalence Of Epidemiological Factors, Stroke Subtypes CPP 02 And Stroke Events: An Observational Study Lim SP1, Loh HC1, Kurubaran G1, Zariah Abdul Aziz 2,3, Looi I1,4 1Clinical Research Centre, Seberang Jaya Hospital, Ministry of Health Malaysia, Penang, Malaysia 2Medical Department, Sultanah Nur Zahirah Hospital, Terengganu, Malaysia 3Clinical Research Centre, Sultanah Nur Zahirah Hospital, Ministry of Health Malaysia, Terengganu, Malaysia 4Medical Department, Seberang Jaya Hospital, Penang, Malaysia Introduction Stroke had been known as a disease of aging but trends were found towards rising stroke incidence at younger age which bring great public health impact as stroke in younger patients carry the potential for greater lifetime burden of disability. Specific definition of young stroke is lacking, the vast majority of authors consider “young stroke” to pertain to individuals under 45 years of age. Age remains as an important non-modifiable risk factor and may be accompanied by multiple comorbidities, particularly for the elderly-aged population which makes worse the prognosis. Method We explored 1373 patient data retrieved from the National Neurology Registry (NNeuR) of Seberang Jaya Hospital (HSJ) between January 2013 and December 2018. Data on patient demographics and stroke manifestations were analysed using descriptive analysis. Results Mean age of gender on stroke admission had reduced to below 60 years old in male patients, while increased to around 70 years old in female patients on last few years. Mean age of ethnic group on stroke admission was rather plateau over the years. Smoking had been the leading risk factor for stroke admission below 60 years old since year 2016. Mean age of haemorrhagic stroke fluctuated over the years, while mean age of ischaemic stroke and transient ischaemic attack showed rather plateau throughout the years. Mean age for first-ever and recurrent stroke had also been reducing to involve young-aged population over the last few years, with youngest age at presentation of both type of stroke event lowest on year 2018. Conclusion Trends towards younger-aged population was noted. More studies on young stroke are needed to understand and reduce their health impact and burden. 6 VIRTUAL E-ABSTRACT Intravenous Thrombolysis In Older Patients With Acute Ischaemic CPP 03 Stroke. Is It Safe In Older Patients In Malaysia? Thiam CN1, Neoh KK 1, Chew SH 1, Swee AHC1, Cheah WK2, Looi I1, 1Hospital Seberang Jaya, Penang, Malaysia 2Hospital Taiping, Perak, Malaysia Background Age is still a barrier to the administration of intravenous thrombolysis (IVT) in acute ischaemic stroke, despite emerging evidence on its effectiveness and safety in older patients. This study aims to look at the safety and functional outcome between young and older patients. Methods Data were extracted from Malaysia National Stroke Registry particularly looking at patients who were admitted to Seberang Jaya Hospital and Taiping Hospital for acute ischaemic stroke and given intravenous thrombolysis from 2012 to September 2019. Safety measures were all intracranial haemorrhage and symptomatic intracranial haemorrhage. Effectiveness and outcome measurements were improvement in NIHSS, modified Rankin Scale at 3 months, and mortality. Results Out of a total of 61 patients who were given IVT, 16 (26.2%) aged 65 or above. The mean age was 56.7(SD=12.6). Only 1 octogenarian was included. There was a statistically significant difference in the median NIHSS on admission between older and younger patients which
Load more

Recommended publications
  • Risk Factors Associated with Necrotising Enterocolitis in Very Low Birth Weight Infants in Malaysian Neonatal Intensive Care Units
    O riginal A rticle Singapore Med J 2012; 53(12) : 826 Risk factors associated with necrotising enterocolitis in very low birth weight infants in Malaysian neonatal intensive care units Nem-Yun Boo1, MRCP, FRCPCH, Irene Guat Sim Cheah2, MRCP, FRCPCH; Malaysian National Neonatal Registry Introduction This study aimed to identify the risk factors associated with necrotising enterocolitis (NEC) in very low birth weight (VLBW; weight < 1,501 g) infants in Malaysian neonatal intensive care units (NICUs). Methods This was a retrospective study based on data collected in a standardised format for all VLBW infants born in 2007 (n = 3,601) and admitted to 31 NICUs in Malaysian public hospitals. A diagnosis of NEC was made based on clinical, radiological and/or histopathological evidence of stage II or III, according to Bell’s criteria. Logistic regression analysis was performed to determine the significant risk factors associated with NEC. ResuLts 222 (6.2%) infants developed NEC (stage II, n = 197; stage III, n = 25). 69 (31.3%) infants died (stage II, n = 58; stage III, n = 11). The significant risk factors associated with NEC were: maternal age (adjusted odds ratio [OR] 1.024, 95% confidence interval [CI] 1.003–1.046; p = 0.027), intrapartum antibiotics (OR 0.639, 95% CI 0.421–0.971; p = 0.036), birth weight (OR 0.999, 95% CI 0.998–0.999; p < 0.001), surfactant therapy (OR 1.590, 95% CI 1.170– 2.161; p = 0.003), congenital pneumonia (OR 2.00, 95% CI 1.405–2.848; p < 0.001) and indomethacin therapy for the closure of patent ductus arteriosus (PDA) (OR 1.821, 95% CI 1.349–2.431; p = 0.001).
    [Show full text]
  • Covid-19) Situation in Malaysia
    PRESS STATEMENT MINISTRY OF HEALTH MALAYSIA UPDATES ON THE CORONAVIRUS DISEASE 2019 (COVID-19) SITUATION IN MALAYSIA Current Status of Confirmed COVID-19 Cases Who Have Recovered 30 April 2020 – The Ministry of Health (MOH) would like to inform that 84 cases have fully recovered and discharged well today. Cumulatively, 4,171 confirmed COVID-19 cases have fully recovered and discharged well (69.5% of total cumulative cases). Current Situation of COVID-19 in Malaysia 30 April 2020, 12 pm – A total of 57 additional confirmed COVID-19 cases were reported to the National Crisis Preparedness and Response Centre (CPRC) MOH today. Cumulatively there are now 6,002 confirmed COVID-19 cases in Malaysia. Therefore, there are currently 1,729 active and infective COVID-19 cases. They have been isolated and provided treatment. Of these 57 additional cases reported today, 25 are imported cases. The remaining 32 cases are due to local transmission. Currently, 36 confirmed COVID-19 cases are receiving treatment in intensive care units (ICU), and of these, 14 cases are on ventilation support. Regretfully, two (2) additional COVID-19 deaths were reported to the National CPRC MOH today. Cumulatively, there are now 102 COVID-19 deaths in Malaysia (1.7% of total cumulative cases): 1. Death #101: Case 4,657 is a 64 year-old Malaysian man with a history of haematological cancer. He was a close contact to a confirmed COVID-19 case (Case 4,476; from the Bali PUI cluster). He was admitted into Tengku Ampuan Afzan Hospital, Pahang on 12 April 2020 and was pronounced dead on 29 April 2020 at 4.14 pm.
    [Show full text]
  • 2 YIA Abstract FA
    YOUNG INVESTIGATOR AWARD NHAM CONGRESS 2019 YOUNG INVESTIGATOR AWARD ABSTRACTS Imaging YIA 1 Time: 1040-1055 Global Longitudinal Strain Predicts Adverse Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction Y.Y. Oon1, K.T. Koh1, K.H. Ho1, C.T. Tan1, F.E.P. Shu1, A. Said1,2, Y.L. Cham1, N.Z. Khiew1, N.H. Mohd Amin1, A.Y.Y. Fong1,3 , T.K. Ong1 1Department of Cardiology, Sarawak Heart Centre 2Faculty of Medicine and Health Sciences, University Malaysia Sarawak 3Clinical Research Centre, Sarawak General Hospital Arrhythmias YIA 2 Time: 1055-1110 Preliminary Results of Smartphone Electrocardiogram for Detecting Atrial Fibrillation After A Cerebral Ischemic Event: A Multi-center Randomised Controlled Trial KT Koh1, Law WC2, Zaw WM2, DHP Foo3, CT Tan1, D Samuel4, TL Fam4, CH Chai4, ZS Wong4, DB Chandan1,5, JSH Tan5, FEP Shu1, KH Ho1, YY Oon1, NZ Khiew1, YL Cham1, A Said1,6, NH Mohd Amin1, AYY Fong1,3, TK Ong1 1Department of Cardiology, Sarawak Heart Centre, Kota Samarahan, Malaysia 2Neurology Unit, Department of Medicine, Sarawak General Hospital, Kuching, Malaysia 3Clinical Research Centre, Sarawak General Hospital, Kuching, Malaysia 4Department of Medicine, Miri Hospital, Malaysia 5Department of Medicine, Bintulu Hospital, Malaysia 6Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, Kota Samarahan, Malaysia Arrhythmias YIA 3 Time: 1110-1125 Prevalence of Atrial Fibrillation Detected by Single-Lead ECG among Senior Citizens at Northern Regions of West Malaysia in 2018 J.G. Ang1, H. Mohamed Hasnan1, K.R. Narasamuloo1, D. Karthikesan1, A.S. Mustafa1, S.S Gian Singh1, J.N. Lim2, A.S. Saad1, 1 1 YOUNG1 1 1 1 1 1 A.F.
    [Show full text]
  • Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia
    A publication of the PHARMACEUTICAL SERVICES DIVISION AND THE CLINICAL RESEARCH CENTRE MINISTRY OF HEALTH MALAYSIA MALAYSIAN STATISTICS ON MEDICINES 2008 Edited by: Lian L.M., Kamarudin A., Siti Fauziah A., Nik Nor Aklima N.O., Norazida A.R. With contributions from: Hafizh A.A., Lim J.Y., Hoo L.P., Faridah Aryani M.Y., Sheamini S., Rosliza L., Fatimah A.R., Nour Hanah O., Rosaida M.S., Muhammad Radzi A.H., Raman M., Tee H.P., Ooi B.P., Shamsiah S., Tan H.P.M., Jayaram M., Masni M., Sri Wahyu T., Muhammad Yazid J., Norafidah I., Nurkhodrulnada M.L., Letchumanan G.R.R., Mastura I., Yong S.L., Mohamed Noor R., Daphne G., Kamarudin A., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Omar I., Zoriah A., Fong Y.Y.A., Nusaibah A.R., Feisul Idzwan M., Ghazali A.K., Hooi L.S., Khoo E.M., Sunita B., Nurul Suhaida B.,Wan Azman W.A., Liew H.B., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Asmah J., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I., Ghazali I., Wan Abu Bakar Y., Wan Hamilton W.H., Ravichandran J., Zaridah S., Wan Zahanim W.Y., Kannappan P., Intan Shafina S., Tan A.L., Rohan Malek J., Selvalingam S., Lei C.M.C., Ching S.L., Zanariah H., Lim P.C., Hong Y.H.J., Tan T.B.A., Sim L.H.B, Long K.N., Sameerah S.A.R., Lai M.L.J., Rahela A.K., Azura D., Ibtisam M.N., Voon F.K., Nor Saleha I.T., Tajunisah M.E., Wan Nazuha W.R., Wong H.S., Rosnawati Y., Ong S.G., Syazzana D., Puteri Juanita Z., Mohd.
    [Show full text]
  • Conjoint Ophthalmology Scientific Conference (COSC 2017)
    Artwork for the 7th Conjoint Ophthalmology Scientific Conference (COSC 2017) Logo COSC 2017 (designed by Dr Aliff Irwan Cheong) The logo symbolizes: 1. “C” represents as the whole eye, and its fluidic and wave like angle shape, exhibit the conference main theme “Angles and Curves”. The inferior tail of the “C” crosses and twist towards the word 2017 represents the conference aim in achieving advancement in Ophthalmology especially in Malaysia. 2. “O” represents the cornea and pupil – exhibit the specialty of interest : Glaucoma & Cornea. 3. “7” signify in RED is a hallmark of conference by COSC 2017. 4. BLUE – Theme color for conference and shown with the year its being held 5. BLACK – Second theme color for conference and shown in the other structure of interest Front Cover Artwork (designed by Dr Tan Li Mun) 1. Image of Cornea and Kuala Lumpur City Centre (KLCC) - Signifies the theme of our conjoint "Angles and Curves" and the location of our event held in Kuala Lumpur 2. Image of Pupil and Iris on the background - Signifies the other parts of anterior segment of the eye. ii Foreword The 7th Conjoint Ophthalmology Scientific Conference (COSC 2017) was held on 15-17 September 2017 at the Pullman Kuala Lumpur Bangsar, Kuala Lumpur. These Scientific Conferences have been held by the Malaysian Universities Conjoint Committee of Ophthalmology every year since 2011, and the theme for this year‟s meeting was „Angles and Curves - New Perspectives on Glaucoma and Cornea Management‟. The programme consisted of workshops, lectures and case discussions conducted by expert international and local speakers, and updated participants on latest developments in the two exciting fields.
    [Show full text]
  • Eighth Report of the Malaysian Dialysis and Transplant Registry for Year 2000 Report Ready Before the End of 2001
    EIGHTH REPORT OF THE MALAYSIAN DIALYSIS AND TRANSPLANT REGISTRY 2000 edited by T. O. LIM Y.N. LIM MALAYSIAN ORGAN SHARING SYSTEM/ NATIONAL RENAL REGISTRY (MOSS/NRR) Malaysian Society of Nephrology c/o Department Of Nephrology Hospital Kuala Lumpur Jalan Pahang 50586 Kuala Lumpur Tel No: 603 2698 4882 Fax No: 603 2691 6514 Email: [email protected] Web site: http://www.crc.gov.my/nrr I ACKNOWLEDGMENT We would like to thank everyone who have toiled to get this eighth report of the Malaysian Dialysis and Transplant Registry for year 2000 report ready before the end of 2001. We have thus managed to produce the seventh and eighth reports this year. We would like to especially thank the following: All centre coordinators, staff, nephrologists and physicians in-charge of dialysis centres and renal units from the various government, non-governmental and private centres without whose dedication and hard work this registry report would not be possible. Ms. Lee Day Guat for her tireless and meticulous effort as data manager Ms Mardhiah bt Arifin, Nur Azliana bt Ramli and Norasiken bt Lajis @ Aziz for their help in data entry. The Ministry of Health, Malaysia for assistance seen and unseen. And of course not forgetting our sponsors Janssen-Cilag, Fresenius Medical Care, Medi- Chem Systems, MX Services, Pharmacia, Novartis Corporation, Glaxo Wellcome and Servier. MOSS/NRR COMMITTEE MALAYSIAN SOCIETY OF NEPHROLOGY II PARTICIPATING CENTRES GOVERNMENT CENTRES 1 801 Rumah Sakit Angkatan Tentera, Kuching 2 807 Rumah Sakit Angkatan Tentera, Sg Petani 3 810
    [Show full text]
  • Prevalence of Chronic Kidney Disease and Its Associated Factors in Malaysia
    Saminathan et al. BMC Nephrology (2020) 21:344 https://doi.org/10.1186/s12882-020-01966-8 RESEARCH ARTICLE Open Access Prevalence of chronic kidney disease and its associated factors in Malaysia; findings from a nationwide population-based cross- sectional study Thamil Arasu Saminathan1* , Lai Seong Hooi2, Muhammad Fadhli Mohd Yusoff1, Loke Meng Ong3, Sunita Bavanandan4, Wan Shakira Rodzlan Hasani1, Esther Zhao Zhi Tan5, Irene Wong6, Halizah Mat Rifin1, Tania Gayle Robert1, Hasimah Ismail1, Norazizah Ibrahim Wong1, Ghazali Ahmad4, Rashidah Ambak1, Fatimah Othman1, Hamizatul Akmal Abd Hamid1 and Tahir Aris1 Abstract Background: The prevalence of chronic kidney disease (CKD) in Malaysia was 9.07% in 2011. We aim to determine the current CKD prevalence in Malaysia and its associated risk factors. Methods: A population-based study was conducted on a total of 890 respondents who were representative of the adult population in Malaysia, i.e., aged ≥18 years old. Respondents were randomly selected using a stratified cluster method. The estimated glomerular filtration rate (eGFR) was estimated from calibrated serum creatinine using the CKD-EPI equation. CKD was defined as eGFR < 60 ml/min/1.73m2 or the presence of persistent albuminuria if eGFR ≥60 ml/min/1.73m2. Results: Our study shows that the prevalence of CKD in Malaysia was 15.48% (95% CI: 12.30, 19.31) in 2018, an increase compared to the year 2011 when the prevalence of CKD was 9.07%. An estimated 3.85% had stage 1 CKD, 4.82% had stage 2 CKD, and 6.48% had stage 3 CKD, while 0.33% had stage 4–5 CKD.
    [Show full text]
  • Hospitals Report-110411.Indd
    NATIONAL HEALTHCARE ESTABLISHMENTS & WORKFORCE STATISTICS 2008-2009 HOSPITALSAAPPENDIPPENDIX1X PARTICIPANTS OF THE NatiONAL Healthcare EstaBLISHMENTS SURVEY 2008-2009 PUBLIC HOSPITALS Public Hospitals (Perlis) 1. Hospital Tuanku Fauziah Public Hospitals (Kedah) 1 Baling Hospital 2 Hospital Sultan Abdul Halim, Sungai Petani 3 Hospital Jitra 4 Hospital Yan 5 Hospital Kuala Nerang 6 Sik Hospital 7 Hospital Kulim 8 Sultanah Bahiyah Hospital, Alor Setar 9 Hospital Langkawi Public Hospitals (Penang) 1 Hospital Balik Pulau 2 Hospital Pulau Pinang 3 Hospital Bukit Mertajam 4 Hospital Seberang Jaya 5 Hospital Kepala Batas 6 Sungai Bakap Hospital Public Hospitals (Perak) 1 Hospital Bahagia, Ulu Kinta 2 Hospital Seri Manjung 3 Hospital Batu Gajah 4 Hospital Slim River 5 Hospital Changkat Melintang 6 Hospital Sungai Siput 7 Hospital Gerik 8 Hospital Taiping 9 Hospital Kampar 10 Hospital Tapah 11 Hospital Kuala Kangsar 12 Hospital Teluk Intan 13 Hospital Parit Buntar 14 Raja Permaisuri Bainun Hospital, Ipoh 15 Hospital Selama Public Hospitals (Selangor) 1 Hospital Ampang 2 Hospital Sungai Buloh 3 Hospital Banting 4 Hospital Tanjong Karang 5 Hospital Kajang 6 Hospital Tengku Ampuan Jemaah 7 Hospital Selayang 8 Hospital Tengku Ampuan Rahimah 9 Hospital Serdang Public Hospitals (Selangor) 1 Hospital Putrajaya Public Hospitals (WP Kuala Lumpur) 1 Hospital Kuala Lumpur 2 Pusat Perubatan Universiti Kebangsaan Malaysia (PPUKM) 3 Institute of Respiratory Medicine 4 University Malaya Medical Centre (UMMC) Public Hospitals (Negri Sembilan) 1 Hospital Jelebu
    [Show full text]
  • SOALAN LAZIM PENYAKIT NOVEL CORONAVIRUS (COVID-19) 15 November 2020
    SOALAN LAZIM PENYAKIT NOVEL CORONAVIRUS (COVID-19) 15 November 2020 Soalan 1: Apakah coronavirus? Coronavirus adalah satu keluarga besar virus yang menyebabkan jangkitan saluran pernafasan seperti Severe Acute Respiratory Syndrome (SARS) dan Middle East Respiratory Syndrome-related Coronavirus (MERS-CoV). Coronavirus terbaharu dan menjadi pandemik di seluruh dunia kini dikenali sebagai Novel Coronavirus 2019 (COVID-19). COVID-19 telah mula dikesan di negara China dengan kes pertama disahkan pada 7 Januari 2020 di Wuhan, Hubei, China. Dalam tempoh tiga (3) minggu seterusnya, kes-kes disahkan di Thailand, Nepal, Amerika Syarikat, Korea Selatan, Singapura, Perancis, Vietnam, Malaysia, Australia, Canada, Cambodia, Sri Lanka dan Jerman. Kes pertama di Malaysia disahkan pada 25 Januari 2020. Sehingga kini, penyakit COVID- 19 masih lagi menular di Malaysia. Sejak 20 September 2020, Malaysia sudah memasuki permulaan gelombang ketiga COVID-19 susulan peningkatan mendadak kes jangkitan virus COVID-19. Kementerian Kesihatan Malaysia dan pihak berkuasa terus menjalankan program dan aktiviti kawalan dan pencegahan bagi membendung wabak COVID-19 di Malaysia. Soalan 2: Bagaimanakah novel coronavirus 2019 (COVID-19) merebak? Cara penularan novel coronavirus COVID-19 daripada individu kepada individu yang lain adalah melalui titisan dari hidung atau mulut yang tersebar apabila seseorang yang dijangkiti COVID-19 batuk atau bersin. Titisan ini melekat pada objek dan permukaan di sekelilingnya. Orang lain yang menyentuh objek atau permukaan ini mempunyai risiko mendapat jangkitan COVID-19 apabila beliau menyentuh mata, hidung atau 1 mulutnya selepas menyentuh permukaan/objek yang tercemar. Seseorang itu juga boleh dijangkiti COVID-19 jika mereka berada dekat dengan pesakit COVID-19 yang batuk, bersin atau bercakap dalam jarak yang dekat.
    [Show full text]
  • Privatisation of Water, Sanitation & Environment-Related Services In
    PRIVATISATION OF WATER, SANITATION & ENVIRONMENT-RELATED SERVICES IN MALAYSIA Japan International Cooperation Agency (JICA) Malaysia Office 1999 JICA...A Study of Privatisation in Malaysia TABLE OF CONTENTS EXECUTIVE SUMMARY.....................................................................................IX CHAPTER 1 A STUDY OF PRIVATISATION IN MALAYSIA: INTRODUCTION................... 1-1 1.1 INTRODUCTION........................................................................................... 1-1 1.2 OBJECTIVES AND SCOPE OF WORK OF THE STUDY ........................................ 1-3 1.3 METHODOLOGY ADOPTED ........................................................................... 1-4 1.4 LITERATURE REVIEW .................................................................................. 1-4 1.5 SCHEDULE OF WORK AND TASKS ................................................................ 1-8 CHAPTER 2 PRIVATISATION IN MALAYSIA: CONCEPT, POLICY AND PRACTISE ........ 2-1 2.1 INTRODUCTION............................................................................................ 2-1 2.2 THE CONCEPT ............................................................................................ 2-2 2.3 THE RATIONALE .......................................................................................... 2-2 2.4 FUTURE DIRECTION..................................................................................... 2-3 2.5 PRIVATISATION POLICY AND PLAN ................................................................. 2-3 2.5.1 Privatisation
    [Show full text]
  • Appendix D: CCU Survey Participation
    Appendix D: CCU Survey Participation APPENDIX D: CCU SURVEY PARTICIPATION We extend our appreciation to the following centres that have contributed in the CCU survey for year 2006, conducted from November 2007 to March 2008: Ampang Hospital Ipoh Hospital Jalan Mewah Utara, Pandan Mewah, Jalan Hospital, 68000 Ampang, 30990 Ipoh, Selangor Perak Ampang Puteri Specialist Hospital Ipoh Specialist Hospital 1 Jalan Mamanda 9, 26 Jalan Raja Dihilir, Taman Dato' Ahmad Razali, 30350 Ipoh, 68000 Ampang, Perak Selangor Assunta Hospital Island Hospital Lot 68 Jalan Templer, 308 Macalister Road, 46990 Petaling Jaya, 10450 Georgetown, Selangor Pulau Pinang Bintulu Hospital Johor Specialist Hospital Jalan Nyabau, 39-B, Jalan Abdul Samad, 97000 Bintulu, 80100 Johor Bahru, Sarawak Johor Bukit Mertajam Hospital Kajang Hospital Jalan Kulim, Jalan Semenyih, 14000 Bukit Mertajam, 43000 Kajang, Seberang Perai, Selangor Pulau Pinang Damansara Specialist Hospital Keningau Hospital 119, Jalan SS20/10 Damansara Utama, KM 5, Jalan Apin-Apin, Keningau, 47400 Petaling Jaya, Peti Surat 11, Selangor 89007 Keningau, Sabah Gleneagles Intan Medical Centre Kepala Batas Hospital 282-286 Jalan Ampang, Jalan Bertam, 50450 Kuala Lumpur 13200 Kepala Batas, Pulau Pinang Gleneagles Medical Centre Koh Cardiology and Medical Clinic Sdn. 1 Jalan Pangkor , Bhd. 10050 Georgetown, Perak Community Specialist Hospital, Pulau Pinang No. 277, Jalan Permaisuri Bainun, 30250 Ipoh, Perak Kuala Lumpur Hospital Normah Medical Specialist Centre Jalan Pahang, Jalan Tun Abdul Rahman, Petra Jaya, 50586 Kuala Lumpur 93050, Kuching Sarawak Kuantan Clinical Diagnostic Centre Pantai Ayer Keroh Hospital Sdn. Bhd. A 37, Jalan Dato' Lim Hoe Lek, No.2418-1, KM 8 Lebuh Ayer Keroh, 25000 Kuantan 75450 Melaka Pahang Report of the Acute Coronary Syndrome (ACS) Registry 2006 164 Appendix D: CCU Survey Participation Kulim Hospital Pantai Indah Hospital Sdn.
    [Show full text]
  • A Randomized Controlled Trial Comparing Peginterferon-Α-2A
    A randomized controlled trial comparing peginterferon-α-2a versus observation after stopping tyrosine kinase inhibitor in chronic myeloid leukemia patients with deep molecular response for at least two years Jew Win Kuan ( [email protected] ) Universiti Malaysia Sarawak https://orcid.org/0000-0003-1686-5570 Kian Meng Chang Ampang Hospital Chin Lee Phan Ampang Hospital Shu Ping Wong Ampang Hospital Soo Min Lim Hospital Sultanah Aminah See Guan Toh Hospital Sultanah Aminah Weng Khean Loh Ampang Hospital Habiba Nazeera Begum Ampang Hospital Siong Leng Hon Ampang Hospital Si Yuan Ng Ampang Hospital Su Kien Chiang Hospital Pulau Pinang Alvin Jung Mau Chai Sibu Hospital: Hospital Sibu Kar Ying Yong Miri Hospital: Hospital Miri Hock Gin Teo Sibu Hospital: Hospital Sibu Page 1/20 Andy Sing Ong Tang Miri Hospital: Hospital Miri Gilbert Wilfred Queen Elizabeth Hospital Yong Khee Guan Hospital Melaka Lily Lee Lee Wong Queen Elizabeth College Ching Tiong Ko Sarawak General Hospital: Hospital Umum Sarawak Research article Keywords: chronic myeloid leukemia, BCR-ABL1, tyrosine kinase inhibitor, treatment free remission, interferon Posted Date: October 21st, 2020 DOI: https://doi.org/10.21203/rs.3.rs-92583/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/20 Abstract Background: Interferon (IFN) is a logical possibility to increase treatment free remission (TFR) rate in chronic myeloid leukemia (CML). We conducted the rst randomized controlled trial comparing the use of pegIFN versus observation in CML patients attempting TFR. Methods: Adult CML patients with stable deep molecular response for ≥ 2 years with ≥2 readings of MR4.5 were randomized into two arms -- subcutaneous pegIFN-α-2a starting at 180µg weekly for a year, followed by observation, or observation.
    [Show full text]